Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Recommendation of "Hold" by Brokerages

Key Points

• Halozyme Therapeutics received an average rating of "Hold" from eleven brokerages, with two sell recommendations, five holds, and four buys.
• CEO Helen Torley sold 20,000 shares of the company for approximately $1.27 million, indicating a 2.65% decrease in her stock ownership.
• For the latest quarter, Halozyme reported an EPS of $1.54, surpassing analyst expectations and marking a 40.8% revenue increase compared to the previous year.

Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) have been assigned an average rating of "Hold" from the eleven analysts that are covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, five have given a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $67.1111.

Several research analysts have weighed in on HALO shares. JPMorgan Chase & Co. increased their price target on shares of Halozyme Therapeutics from $60.00 to $63.00 and gave the company a "neutral" rating in a report on Thursday, August 7th. Benchmark lowered shares of Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, May 7th. Leerink Partnrs lowered shares of Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Tuesday, May 13th. Wells Fargo & Company lifted their price target on shares of Halozyme Therapeutics from $60.00 to $65.00 and gave the stock an "equal weight" rating in a report on Wednesday, May 7th. Finally, The Goldman Sachs Group initiated coverage on shares of Halozyme Therapeutics in a report on Thursday, July 10th. They set a "neutral" rating and a $55.00 price target on the stock.

Insiders Place Their Bets

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $63.51, for a total value of $1,270,200.00. Following the completion of the sale, the chief executive officer directly owned 733,719 shares of the company's stock, valued at approximately $46,598,493.69. The trade was a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have sold 80,000 shares of company stock valued at $4,532,600 over the last ninety days. Insiders own 2.40% of the company's stock.

Institutional Investors Weigh In On Halozyme Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Heck Capital Advisors LLC bought a new stake in Halozyme Therapeutics in the fourth quarter valued at $29,000. Wealth Preservation Advisors LLC bought a new stake in Halozyme Therapeutics in the first quarter valued at $32,000. Newbridge Financial Services Group Inc. bought a new stake in Halozyme Therapeutics in the second quarter valued at $32,000. SVB Wealth LLC bought a new stake in Halozyme Therapeutics in the first quarter valued at $33,000. Finally, Bessemer Group Inc. increased its stake in Halozyme Therapeutics by 62.9% in the first quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company's stock valued at $34,000 after purchasing an additional 207 shares in the last quarter. 97.79% of the stock is owned by institutional investors.

Halozyme Therapeutics Stock Performance

Shares of HALO stock traded up $0.16 on Tuesday, reaching $72.97. The stock had a trading volume of 325,318 shares, compared to its average volume of 1,960,204. The company has a quick ratio of 7.01, a current ratio of 8.36 and a debt-to-equity ratio of 4.54. The firm's 50-day moving average is $60.28 and its two-hundred day moving average is $59.16. The firm has a market capitalization of $8.54 billion, a price-to-earnings ratio of 16.69, a P/E/G ratio of 0.42 and a beta of 1.17. Halozyme Therapeutics has a 12 month low of $42.01 and a 12 month high of $74.07.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.23 by $0.31. The company had revenue of $325.72 million for the quarter, compared to analysts' expectations of $282.66 million. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. Halozyme Therapeutics's quarterly revenue was up 40.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.91 EPS. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. On average, research analysts expect that Halozyme Therapeutics will post 4.73 EPS for the current fiscal year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.